Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience.
CTD-ILD
ILD
connective tissue interstitial lung disease
nintedanib
real-world data
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
23 Mar 2023
23 Mar 2023
Historique:
received:
15
02
2023
revised:
19
03
2023
accepted:
21
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but their efficacy in ILD progression remains uncertain. Nintedanib, an antifibrotic agent that slows pulmonary function decline, has been approved for CTD-ILD treatment. The aim of this study was to assess the effectiveness and safety of nintedanib in CTD-ILD patients in a real-world data setting. A single-center, retrospective, and descriptive analysis of CTD-ILD patients treated with nintedanib from June 2019 to November 2022 was performed. The assessment of nintedanib treatment's efficacy was judged solely on the evolution of pulmonary function tests (PFTs), which were evaluated before and after treatment. Twenty-one patients (67% females, median age 64 years (IQR = 9) with CTD-ILD (systemic sclerosis
Identifiants
pubmed: 37046439
pii: diagnostics13071221
doi: 10.3390/diagnostics13071221
pmc: PMC10093288
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Autoimmun Rev. 2021 Jun;20(6):102830
pubmed: 33887489
Curr Pulmonol Rep. 2022;11(3):86-98
pubmed: 35530438
Eur Respir J. 2022 Jul 13;60(1):
pubmed: 34949706
BMJ Open Respir Res. 2017 Sep 17;4(1):e000212
pubmed: 29018526
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Respir Res. 2022 Apr 7;23(1):85
pubmed: 35392908
RMD Open. 2022 Nov;8(2):
pubmed: 36328401
Intern Emerg Med. 2017 Apr;12(3):319-326
pubmed: 27888395
Curr Opin Pharmacol. 2022 Aug;65:102245
pubmed: 35662004
Curr Opin Pulm Med. 2019 Sep;25(5):442-449
pubmed: 31365378
Respir Investig. 2021 Jan;59(1):99-105
pubmed: 32891571
Clin Pharmacokinet. 2019 Sep;58(9):1131-1147
pubmed: 31016670
Arthritis Rheumatol. 2022 Mar;74(3):518-526
pubmed: 34514739
Front Med (Lausanne). 2021 Feb 03;8:626953
pubmed: 33614683
Lancet Respir Med. 2016 Sep;4(9):708-719
pubmed: 27469583
Arthritis Rheumatol. 2022 Jan;74(1):13-27
pubmed: 34313399
Lancet Respir Med. 2023 Jan;11(1):45-54
pubmed: 36375479
Biomedicines. 2022 Aug 15;10(8):
pubmed: 36009520
Expert Rev Respir Med. 2017 May;11(5):343-359
pubmed: 28345383
Respir Investig. 2021 Nov;59(6):709-740
pubmed: 34602377
Eur Respir Rev. 2021 Mar 24;30(159):
pubmed: 33762426
Mediterr J Rheumatol. 2018 Dec 18;29(4):236-238
pubmed: 32185335
Clin Rheumatol. 2021 Dec;40(12):4861-4867
pubmed: 34313866
Lung. 2020 Oct;198(5):735-759
pubmed: 32780179
Arthritis Rheumatol. 2021 Jul;73(7):1301-1310
pubmed: 33538094
Respir Res. 2021 Mar 16;22(1):84
pubmed: 33726766
Mediterr J Rheumatol. 2018 Sep 27;29(3):140-147
pubmed: 32185315
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
Respiration. 2015;90(1):2-24
pubmed: 26138258
Am J Respir Crit Care Med. 2017 Nov 3;197(5):644-652
pubmed: 29099620
Pulmonology. 2022 Mar-Apr;28(2):113-118
pubmed: 32044296
Adv Ther. 2023 Apr;40(4):1474-1493
pubmed: 36692681
Pulmonology. 2020 Jan - Feb;26(1):1-2
pubmed: 31653592
Rheumatology (Oxford). 2017 Aug 1;56(8):1348-1357
pubmed: 28444364
Respiration. 2018;96(6):571-587
pubmed: 30308515
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Drugs. 2021 Apr;81(5):575-586
pubmed: 33765296
Arthritis Rheumatol. 2022 Jun;74(6):1039-1047
pubmed: 35199968
Arthritis Res Ther. 2022 Jan 10;24(1):19
pubmed: 35012623
PLoS One. 2022 Feb 3;17(2):e0262795
pubmed: 35113907
Drugs Context. 2021 Jan 15;10:
pubmed: 33505482
Eur Respir Rev. 2018 Dec 21;27(150):
pubmed: 30578333
Mediterr J Rheumatol. 2020 Sep 30;31(3):330-336
pubmed: 33163866
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Front Immunol. 2022 Nov 23;13:925776
pubmed: 36505455
Front Med (Lausanne). 2017 Aug 02;4:123
pubmed: 28824912
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32
pubmed: 28992174
Ann Rheum Dis. 2021 Feb;80(2):143-150
pubmed: 33037004
Acta Reumatol Port. 2019 May 18;44(2):161-162
pubmed: 31280278
J Clin Med. 2020 Apr 10;9(4):
pubmed: 32290218
Mediterr J Rheumatol. 2019 Mar 28;30(1):33-37
pubmed: 32185340
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
J Rheumatol. 2015 Nov;42(11):2168-71
pubmed: 25729034
Pneumologie. 2010 Aug;64(8):496-503
pubmed: 20387195
Clin Exp Rheumatol. 2018 Sep-Oct;36 Suppl 114(5):165-170
pubmed: 30296990
Mediterr J Rheumatol. 2019 Sep 30;30(3):147-154
pubmed: 32185357